Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541444
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-07
Brief Title:
Safety and Efficacy of NK520 to Treat RelapsedRefractory Acute Myeloid Leukemia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Patients With RelapsedRefractory Acute Myeloid Leukemia
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsedrefractory acute myeloid leukemia NK520 will be administered by intravenous injection The safety and efficacy of this treatment will be evaluated
Detailed Description:
This open label single-arm study aims to evaluate the efficacy and safety of allogenic NK cells in subjects with relapsedrefractory acute myeloid leukemia Allogenic NK cells will be infused once a week After infusion the investigators will observe the characteristics of dose limited toxicity DLT and determine the maximum tolerable doseMTD To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None